Yassin Belahnech, Eduard Ródenas-Alesina, Miguel Ángel Muñoz, Jose María Verdu-Rotellar, Augusto Sao-Avilés, Garazi Urio-Garmendia, Dimelza Osorio, Karla Salas, Efrain Pantoja, Aida Ribera, Ignacio Ferreira-González
{"title":"老年人系统性冠状动脉风险评估 2(SCORE2-OP):10 年风险验证、临床实用性和潜在改进。","authors":"Yassin Belahnech, Eduard Ródenas-Alesina, Miguel Ángel Muñoz, Jose María Verdu-Rotellar, Augusto Sao-Avilés, Garazi Urio-Garmendia, Dimelza Osorio, Karla Salas, Efrain Pantoja, Aida Ribera, Ignacio Ferreira-González","doi":"10.1093/eurjpc/zwae383","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>European Systematic Coronary Risk Assessment 2 for Older Persons (SCORE2-OP) model has shown modest performance when externally validated in selected cohorts. We aim to investigate its predictive performance and clinical utility for 10-years cardiovascular (CV) risk in an unbiased and representative cohort of older people of a low CV risk country. Furthermore, we explore whether other clinical or echocardiographic features could improve its performance.</p><p><strong>Methods and results: </strong>A cohort of randomly selected individuals ≥ 65 years from a primary care population of Barcelona without established cardiovascular disease included 791 patients (63.1% female, median age 76 years, median follow-up 11.8 years). The model's performance yielded a Harrell's C-statistic of 0.706 (95% CI 0.659-0.753) for the primary endpoint (myocardial infarction, stroke, cardiovascular mortality) and 0.692 (95% CI 0.649-0.734) for the secondary endpoint (primary endpoint plus heart failure hospitalization), with better discrimination in females. SCORE2-OP underestimated the risk of primary endpoint in women (Expected[E]/Observed[O]=0.77), slightly overestimated in men (E/O=1.06), and systematically underestimated the risk of the secondary endpoint (E/O=0.52). Decision curve analysis showed net clinical benefit across a 7.5-30% risk range for primary endpoint. Valvular calcification was the only variable that significantly improved 10-year SCORE2-OP risk performance for both primary and secondary endpoints, with a change in Harrell's C of 0.028 (P=0.017).</p><p><strong>Conclusion: </strong>In a low CV risk country, SCORE2-OP showed notable discrimination and excellent calibration to predict 10-year cardiovascular risk, with better performance in females. Incorporating valvular calcification in a future revised score may enhance accuracy and reduce unnecessary treatments.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic Coronary Risk Evaluation 2 for Older Persons (SCORE2-OP): 10 years risk validation, clinical utility and potential improvement.\",\"authors\":\"Yassin Belahnech, Eduard Ródenas-Alesina, Miguel Ángel Muñoz, Jose María Verdu-Rotellar, Augusto Sao-Avilés, Garazi Urio-Garmendia, Dimelza Osorio, Karla Salas, Efrain Pantoja, Aida Ribera, Ignacio Ferreira-González\",\"doi\":\"10.1093/eurjpc/zwae383\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>European Systematic Coronary Risk Assessment 2 for Older Persons (SCORE2-OP) model has shown modest performance when externally validated in selected cohorts. We aim to investigate its predictive performance and clinical utility for 10-years cardiovascular (CV) risk in an unbiased and representative cohort of older people of a low CV risk country. Furthermore, we explore whether other clinical or echocardiographic features could improve its performance.</p><p><strong>Methods and results: </strong>A cohort of randomly selected individuals ≥ 65 years from a primary care population of Barcelona without established cardiovascular disease included 791 patients (63.1% female, median age 76 years, median follow-up 11.8 years). The model's performance yielded a Harrell's C-statistic of 0.706 (95% CI 0.659-0.753) for the primary endpoint (myocardial infarction, stroke, cardiovascular mortality) and 0.692 (95% CI 0.649-0.734) for the secondary endpoint (primary endpoint plus heart failure hospitalization), with better discrimination in females. SCORE2-OP underestimated the risk of primary endpoint in women (Expected[E]/Observed[O]=0.77), slightly overestimated in men (E/O=1.06), and systematically underestimated the risk of the secondary endpoint (E/O=0.52). Decision curve analysis showed net clinical benefit across a 7.5-30% risk range for primary endpoint. Valvular calcification was the only variable that significantly improved 10-year SCORE2-OP risk performance for both primary and secondary endpoints, with a change in Harrell's C of 0.028 (P=0.017).</p><p><strong>Conclusion: </strong>In a low CV risk country, SCORE2-OP showed notable discrimination and excellent calibration to predict 10-year cardiovascular risk, with better performance in females. Incorporating valvular calcification in a future revised score may enhance accuracy and reduce unnecessary treatments.</p>\",\"PeriodicalId\":12051,\"journal\":{\"name\":\"European journal of preventive cardiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of preventive cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/eurjpc/zwae383\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwae383","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的:欧洲老年人系统性冠状动脉风险评估 2(SCORE2-OP)模型在选定的队列中经过外部验证后显示出适度的性能。我们的目的是在一个低冠心病风险国家的无偏见、有代表性的老年人队列中,研究该模型对 10 年心血管(CV)风险的预测性能和临床实用性。此外,我们还探讨了其他临床或超声心动图特征是否能提高其性能:我们从巴塞罗那的初级保健人群中随机抽取了 791 名年龄≥ 65 岁且无心血管疾病的患者(63.1% 为女性,中位年龄为 76 岁,中位随访时间为 11.8 年)。该模型的主要终点(心肌梗死、中风、心血管病死亡率)的哈雷尔 C 统计量为 0.706(95% CI 0.659-0.753),次要终点(主要终点加心衰住院)的哈雷尔 C 统计量为 0.692(95% CI 0.649-0.734),对女性的区分度更高。SCORE2-OP低估了女性主要终点的风险(预期[E]/观察[O]=0.77),略微高估了男性主要终点的风险(E/O=1.06),系统性低估了次要终点的风险(E/O=0.52)。决策曲线分析显示,主要终点的净临床获益风险范围为7.5%-30%。瓣膜钙化是唯一能显著改善SCORE2-OP 10年主要和次要终点风险表现的变量,哈雷尔C值变化为0.028(P=0.017):结论:在一个心血管疾病风险较低的国家,SCORE2-OP 在预测 10 年心血管疾病风险方面表现出显著的辨别力和出色的校准能力,女性的表现更好。在未来修订的评分中纳入瓣膜钙化可能会提高准确性并减少不必要的治疗。
Systematic Coronary Risk Evaluation 2 for Older Persons (SCORE2-OP): 10 years risk validation, clinical utility and potential improvement.
Aims: European Systematic Coronary Risk Assessment 2 for Older Persons (SCORE2-OP) model has shown modest performance when externally validated in selected cohorts. We aim to investigate its predictive performance and clinical utility for 10-years cardiovascular (CV) risk in an unbiased and representative cohort of older people of a low CV risk country. Furthermore, we explore whether other clinical or echocardiographic features could improve its performance.
Methods and results: A cohort of randomly selected individuals ≥ 65 years from a primary care population of Barcelona without established cardiovascular disease included 791 patients (63.1% female, median age 76 years, median follow-up 11.8 years). The model's performance yielded a Harrell's C-statistic of 0.706 (95% CI 0.659-0.753) for the primary endpoint (myocardial infarction, stroke, cardiovascular mortality) and 0.692 (95% CI 0.649-0.734) for the secondary endpoint (primary endpoint plus heart failure hospitalization), with better discrimination in females. SCORE2-OP underestimated the risk of primary endpoint in women (Expected[E]/Observed[O]=0.77), slightly overestimated in men (E/O=1.06), and systematically underestimated the risk of the secondary endpoint (E/O=0.52). Decision curve analysis showed net clinical benefit across a 7.5-30% risk range for primary endpoint. Valvular calcification was the only variable that significantly improved 10-year SCORE2-OP risk performance for both primary and secondary endpoints, with a change in Harrell's C of 0.028 (P=0.017).
Conclusion: In a low CV risk country, SCORE2-OP showed notable discrimination and excellent calibration to predict 10-year cardiovascular risk, with better performance in females. Incorporating valvular calcification in a future revised score may enhance accuracy and reduce unnecessary treatments.
期刊介绍:
European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.